Completed
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
NCT00050440
- Conditions
- Carcinoma, Endometrial Neoplasms, Female Urogenital Diseases, +13 more
- Locations
-
- Los Angeles, California, United States
- Miami, Florida, United States
- Lexington, Kentucky, United States
- Baltimore, Maryland, United States